albuterol has been researched along with Complete Breech in 7 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied 90 breech presentations in late pregnancy who did not have contra-indications to ECV." | 2.66 | A prospective randomised controlled trial of external cephalic version comparing two methods of uterine tocolysis with a non-tocolysis group. ( Jen, SW; Salmon, YM; Tan, GW; Tan, SL, 1989) |
| "Sixty-eight women with breech presentation at around 36 weeks of gestation and an attempted external cephalic version under salbutamol that failed, who consented to try a second attempt under epidural anaesthesia." | 1.31 | External cephalic version with epidural anaesthesia after failure of a first trial with beta-mimetics. ( Blanié, P; de Spirlet, M; Durand-Zaleski, I; Fisher, C; Goffinet, F; Lang, AC; Nisand, I; Rozenberg, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Levin, G | 1 |
| Cahan, T | 1 |
| Weill, Y | 1 |
| Axelrod, M | 1 |
| Pollack, RN | 1 |
| Meyer, R | 1 |
| Birene, B | 1 |
| Ishaque, U | 1 |
| Chrusciel, J | 1 |
| Bonneau, S | 1 |
| Gabriel, R | 1 |
| Graesslin, O | 1 |
| Vani, S | 1 |
| Lau, SY | 1 |
| Lim, BK | 1 |
| Omar, SZ | 1 |
| Tan, PC | 1 |
| Tasnim, N | 1 |
| Mahmud, G | 1 |
| Khurshid, M | 1 |
| Sellappah, S | 1 |
| Wagman, H | 1 |
| Rozenberg, P | 1 |
| Goffinet, F | 1 |
| de Spirlet, M | 1 |
| Durand-Zaleski, I | 1 |
| Blanié, P | 1 |
| Fisher, C | 1 |
| Lang, AC | 1 |
| Nisand, I | 1 |
| Tan, GW | 1 |
| Jen, SW | 1 |
| Tan, SL | 1 |
| Salmon, YM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Success of External Cephalic Version With Immediate Spinal Anesthesia Versus Spinal Anesthesia When Attempt Without Anesthesia Has Failed: A Randomized Controlled Trial[NCT03106753] | Phase 4 | 34 participants (Actual) | Interventional | 2017-04-12 | Terminated (stopped due to Interim analysis to assess concern for spinal anesthesia and increased cesarean delivery rate.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Arterial cord pH level (NCT03106753)
Timeframe: Day 1
| Intervention | pH (Mean) |
|---|---|
| Spinal Anesthesia Immediately for ECV. | 7.2 |
| Spinal Anesthesia if no Intervention Fails for ECV. | 7.2 |
Newborn birth weight in grams. (NCT03106753)
Timeframe: Day 1 of delivery
| Intervention | grams (Mean) |
|---|---|
| Spinal Anesthesia Immediately for ECV. | 3321.6 |
| Spinal Anesthesia if no Intervention Fails for ECV. | 3257.7 |
Number of total specific adverse events such as: fetal bradycardia, emergent cesarean section, or abruption. (NCT03106753)
Timeframe: Day 1
| Intervention | events (Number) |
|---|---|
| Spinal Anesthesia Immediately for ECV. | 11 |
| Spinal Anesthesia if no Intervention Fails for ECV. | 5 |
Number of patients whose neonate was admitted to the NICU in each group. (NCT03106753)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Spinal Anesthesia Immediately for ECV. | 1 |
| Spinal Anesthesia if no Intervention Fails for ECV. | 1 |
Number of days from procedure to delivery. (NCT03106753)
Timeframe: up to day 42
| Intervention | hours (Mean) |
|---|---|
| Spinal Anesthesia Immediately for ECV. | 12.6 |
| Spinal Anesthesia if no Intervention Fails for ECV. | 11.3 |
Newborns with Apgar Score 7 or 9 at 5 minutes after delivery. The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health. (NCT03106753)
Timeframe: 7 minutes and 9 minutes after delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 7 | 9 | |
| Spinal Anesthesia if no Intervention Fails for ECV. | 1 | 15 |
| Spinal Anesthesia Immediately for ECV. | 1 | 16 |
Success rate will be measured by comparing the percentage of successful external cephalic versions in each group. (NCT03106753)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Nulliparous | Multiparous | |
| Spinal Anesthesia if no Intervention Fails for ECV. | 5 | 3 |
| Spinal Anesthesia Immediately for ECV. | 4 | 3 |
Mode of delivery as incidence of spontaneous vaginal delivery, operative vaginal delivery, or cesarean section. (NCT03106753)
Timeframe: up to day 42
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Spontaneous Vaginal Delivery | Operative Vaginal Delivery | Cesarean Section | |
| Spinal Anesthesia if no Intervention Fails for ECV. | 6 | 1 | 9 |
| Spinal Anesthesia Immediately for ECV. | 6 | 0 | 11 |
Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1
| Intervention | score on a scale (Mean) |
|---|---|
| First procedure | |
| Spinal Anesthesia Immediately for ECV. | 2.0 |
Patient discomfort rated with NRS-11. Total scale from 0-10, with higher score indicating more pain. (NCT03106753)
Timeframe: Day 1
| Intervention | score on a scale (Mean) | |
|---|---|---|
| First procedure | Second procedure | |
| Spinal Anesthesia if no Intervention Fails for ECV. | 6.1 | 2.2 |
2 trials available for albuterol and Complete Breech
| Article | Year |
|---|---|
Intravenous salbutamol for external cephalic version.
Topics: Adult; Albuterol; Breech Presentation; Cesarean Section; Female; Humans; Infusions, Intravenous; Pre | 2009 |
A prospective randomised controlled trial of external cephalic version comparing two methods of uterine tocolysis with a non-tocolysis group.
Topics: Adult; Albuterol; Breech Presentation; Delivery, Obstetric; Female; Gestational Age; Humans; Infant, | 1989 |
5 other studies available for albuterol and Complete Breech
| Article | Year |
|---|---|
Ritodrine versus salbutamol for external cephalic version.
Topics: Albuterol; Breech Presentation; Female; Humans; Infant, Newborn; Placenta; Pregnancy; Prospective St | 2022 |
Influence of the external cephalic version attempt on the Cesarean section rate: experience of a type 3 maternity hospital in France.
Topics: Adult; Albuterol; Breech Presentation; Cardiotocography; Cesarean Section; Delivery, Obstetric; Fema | 2021 |
External cephalic version with salbutamol - success rate and predictors of success.
Topics: Adult; Albuterol; Amniotic Fluid; Breech Presentation; Cesarean Section; Female; Gestational Age; Hu | 2009 |
Management of breech presentation.
Topics: Albuterol; Breech Presentation; Delivery, Obstetric; Female; Humans; Labor Presentation; Pregnancy; | 1983 |
External cephalic version with epidural anaesthesia after failure of a first trial with beta-mimetics.
Topics: Adrenergic beta-Agonists; Albuterol; Anesthesia, Epidural; Anesthesia, Obstetrical; Apgar Score; Bre | 2000 |